Effects of Selegiline, a Monoamine Oxidase B Inhibitor, on Differentiation of P19 Embryonal Carcinoma Stem Cells, into Neuron-like Cells

Overview

Journal In Vitro Cell Dev Biol Anim

Publisher Springer

Specialties Biology
Cell Biology

Date 2011 Aug 23

PMID 21858609

Citations 4

Authors

Shabnam Bakhshalizadeh

Fariba Esmaeili

Fariba Houshmand

Hedayatollah Shirzad

Mojtaba Saedi

Affiliations

Soon will be listed here.

Abstract

Selegiline, the irreversible inhibitor of monoamine oxidase B (MAO-B), is currently used to treat Parkinson's disease. However, the mechanism of action of selegiline is complex and cannot be explained solely by its MAO-B inhibitory action. It stimulates gene expression, as well as expression of a number of mRNAs or proteins in nerve and glial cells. Direct neuroprotective and anti-apoptotic actions of selegiline have previously been observed in vitro. Previous studies showed that selegiline can induce neuronal phenotype in cultured bone marrow stem cells and embryonic stem cells. Embryonal carcinoma (EC) cells are developmentally pluripotene cells which can be differentiated into all cell types under the appropriate conditions. The present study was carried out to examine the effects of selegiline on undifferentiated P19 EC cells. The results showed that selegiline treatment had a dramatic effect on neuronal morphology. It induced the differentiation of EC cells into neuron-like cells in a concentration-dependent manner. The peak response was in a dose of selegiline significantly lower than required for MAO-B inhibition. The differentiated cells were immunoreactive for neuron-specific proteins, synaptophysin, and β-III tubulin. Stem cell therapy has been considered as an ideal option for the treatment of neurodegenerative diseases. Generation of neurons from stem cells could serve as a source for potential cell therapy. This study suggests the potential use of combined selegiline and stem cell therapy to improve deficits in neurodegenerative diseases.

Citing Articles

Expression of neurotrophic factor genes by human adipose stem cells post-induction by deprenyl.

Amiri A, Kashani M, Taghi Ghorbanian M Anat Cell Biol. 2021; 54(1):74-82.

PMID: 33526752 PMC: 8017458. DOI: 10.5115/acb.19.229.

Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Szoko E, Tabi T, Riederer P, Vecsei L, Magyar K J Neural Transm (Vienna). 2018; 125(11):1735-1749.

PMID: 29417334 DOI: 10.1007/s00702-018-1853-9.

Oxidative stress and age-related changes in T cells: is thalassemia a model of accelerated immune system aging?.

Ghatreh-Samani M, Esmaeili N, Soleimani M, Asadi-Samani M, Ghatreh-Samani K, Shirzad H Cent Eur J Immunol. 2016; 41(1):116-24.

PMID: 27095931 PMC: 4829813. DOI: 10.5114/ceji.2015.56973.

Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for differentiation therapy.

Ali Hosseini Rad S, Bamdad T, Sadeghizadeh M, Arefian E, Lotfinia M, Ghanipour M Tumour Biol. 2014; 36(4):2621-9.

PMID: 25464862 DOI: 10.1007/s13277-014-2884-y.

References

Fraichard A, Chassande O, Bilbaut G, Dehay C, Savatier P, Samarut J . In vitro differentiation of embryonic stem cells into glial cells and functional neurons. J Cell Sci. 1995; 108 ( Pt 10):3181-8. DOI: 10.1242/jcs.108.10.3181. View

Jagla W, Wiede A, Dietzmann K, Rutkowski K, Hoffmann W . Co-localization of TFF3 peptide and oxytocin in the human hypothalamus. FASEB J. 2000; 14(9):1126-31. DOI: 10.1096/fasebj.14.9.1126. View

Kompisch K, Lange C, Steinemann D, Skawran B, Schlegelberger B, Muller R . Neurogenic transdifferentiation of human adipose-derived stem cells? A critical protocol reevaluation with special emphasis on cell proliferation and cell cycle alterations. Histochem Cell Biol. 2010; 134(5):453-68. DOI: 10.1007/s00418-010-0740-8. View

Passier R, Mummery C . Origin and use of embryonic and adult stem cells in differentiation and tissue repair. Cardiovasc Res. 2003; 58(2):324-35. DOI: 10.1016/s0008-6363(02)00770-8. View

Andrews P, Damjanov I, Simon D, Banting G, Carlin C, Dracopoli N . Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. Lab Invest. 1984; 50(2):147-62. View

He Q, Li J, Bettiol E, Jaconi M . Embryonic stem cells: new possible therapy for degenerative diseases that affect elderly people. J Gerontol A Biol Sci Med Sci. 2003; 58(3):279-87. DOI: 10.1093/gerona/58.3.m279. View

McBurney M, Rogers B . Isolation of male embryonal carcinoma cells and their chromosome replication patterns. Dev Biol. 1982; 89(2):503-8. DOI: 10.1016/0012-1606(82)90338-4. View

Falconer M, Echeverri C, Brown D . Differential sorting of beta tubulin isotypes into colchicine-stable microtubules during neuronal and muscle differentiation of embryonal carcinoma cells. Cell Motil Cytoskeleton. 1992; 21(4):313-25. DOI: 10.1002/cm.970210407. View

Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin M . Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice. J Neurosci. 2010; 30(43):14299-304. PMC: 2972675. DOI: 10.1523/JNEUROSCI.3383-10.2010. View

10.

McBurney M . Clonal lines of teratocarcinoma cells in vitro: differentiation and cytogenetic characteristics. J Cell Physiol. 1976; 89(3):441-55. DOI: 10.1002/jcp.1040890310. View

11.

Xu L, Ma J, Seigel G, Ma J . l-Deprenyl, blocking apoptosis and regulating gene expression in cultured retinal neurons. Biochem Pharmacol. 1999; 58(7):1183-90. DOI: 10.1016/s0006-2952(99)00208-7. View

12.

Schmidt M, Guan K, Wobus A . Lithium influences differentiation and tissue-specific gene expression of mouse embryonic stem (ES) cells in vitro. Int J Dev Biol. 2001; 45(2):421-9. View

13.

Masliah E, Terry R . The role of synaptic proteins in the pathogenesis of disorders of the central nervous system. Brain Pathol. 1993; 3(1):77-85. DOI: 10.1111/j.1750-3639.1993.tb00728.x. View

14.

Davidson C, Chen Q, Zhang X, Xiong X, Lazarus C, Lee T . Deprenyl treatment attenuates long-term pre- and post-synaptic changes evoked by chronic methamphetamine. Eur J Pharmacol. 2007; 573(1-3):100-10. DOI: 10.1016/j.ejphar.2007.06.046. View

15.

Klegeris A, McGeer P . R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Exp Neurol. 2000; 166(2):458-64. DOI: 10.1006/exnr.2000.7517. View

16.

McBurney M, Rogers K, Kalnins V . Retinoic acid induces embryonal carcinoma cells to differentiate into neurons and glial cells. J Cell Biol. 1982; 94(2):253-62. PMC: 2112882. DOI: 10.1083/jcb.94.2.253. View

17.

Rak K, Wasielewski N, Radeloff A, Volkers J, Scherzed A, Jablonka S . Isolation and characterization of neural stem cells from the neonatal rat cochlear nucleus. Cell Tissue Res. 2011; 343(3):499-508. DOI: 10.1007/s00441-010-1118-x. View

18.

Tatton W, Chalmers-Redman R . Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 1996; 47(6 Suppl 3):S171-83. DOI: 10.1212/wnl.47.6_suppl_3.171s. View

19.

Palfi M, Szoko E, Kalman M . [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl]. Orv Hetil. 2006; 147(27):1251-7. View

20.

Bailey J, Lahiri D . A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem. 2009; 112(4):843-53. PMC: 2881332. DOI: 10.1111/j.1471-4159.2009.06490.x. View